Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Capital Expenditures (2020 - 2024)

Historic Capital Expenditures for HCW Biologics (HCWB) over the last 5 years, with Q4 2024 value amounting to $99780.0.

  • HCW Biologics' Capital Expenditures fell 9731.46% to $99780.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $99780.0, marking a year-over-year decrease of 9822.66%. This contributed to the annual value of $2.0 million for FY2024, which is 6758.65% down from last year.
  • As of Q4 2024, HCW Biologics' Capital Expenditures stood at $99780.0, which was down 9731.46% from $141077.0 recorded in Q3 2024.
  • HCW Biologics' Capital Expenditures' 5-year high stood at $10.2 million during Q3 2022, with a 5-year trough of -$422634.0 in Q2 2024.
  • In the last 5 years, HCW Biologics' Capital Expenditures had a median value of $99780.0 in 2024 and averaged $1.1 million.
  • As far as peak fluctuations go, HCW Biologics' Capital Expenditures surged by 24602729.91% in 2022, and later crashed by 12715.26% in 2024.
  • Quarter analysis of 5 years shows HCW Biologics' Capital Expenditures stood at $36391.0 in 2020, then tumbled by 45.45% to $19852.0 in 2021, then soared by 246.0% to $68687.0 in 2022, then skyrocketed by 5309.54% to $3.7 million in 2023, then plummeted by 97.31% to $99780.0 in 2024.
  • Its Capital Expenditures was $99780.0 in Q4 2024, compared to $141077.0 in Q3 2024 and -$422634.0 in Q2 2024.